Autonomix Medical, Inc. (AMIX) shared positive preliminary results from its first five lead-in patients in a proof-of-concept trial. The trial assesses the safety and effectiveness of Autonomix's proprietary radiofrequency (RF) ablation technology, designed to ablate targeted nerves and reduce pain in late-stage pancreatic cancer patients. Among participants, three treated through femoral access experienced significant pain reduction — from a mean score of 8 to 1.33 on the Visual Analog Scale — and were abl ...